Aleksandra Marchwicka
Overview
Explore the profile of Aleksandra Marchwicka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Brown G, Marchwicka A, Cunningham A, Toellner K, Marcinkowska E
Arch Immunol Ther Exp (Warsz)
. 2016 Jul;
65(1):69-81.
PMID: 27412076
Activities of the retinoic acid receptor (RAR)α and RARγ are important to hematopoiesis. Here, we have investigated the effects of receptor selective agonists and antagonists on the primitive human hematopoietic...
12.
Marchwicka A, Cunningham A, Marcinkowska E, Brown G
Expert Opin Ther Pat
. 2016 Jun;
26(8):957-71.
PMID: 27336223
Introduction: Differentiation therapy using all-trans retinoic acid (ATRA) revolutionised the treatment of acute promyelocytic leukaemia to such an extent that it is now one of the most curable types of...
13.
Marchwicka A, Cebrat M, Laszkiewicz A, Sniezewski L, Brown G, Marcinkowska E
J Steroid Biochem Mol Biol
. 2016 Mar;
159:121-30.
PMID: 26969398
Acute myeloid leukemia (AML) is the predominant acute leukemia among adults, characterized by an accumulation of malignant immature myeloid precursors. A very promising way to treat AML is differentiation therapy...
14.
Marchwicka A, Corcoran A, Berkowska K, Marcinkowska E
Cell Biosci
. 2016 Feb;
6:7.
PMID: 26839680
Background: Acute myeloid leukemia (AML) cells can be induced to undergo terminal differentiation with subsequent loss of tumorigenicity using 1,25-dihydroxyvitamin D3 (1,25D) alone or in combination with hematopoietic cytokines. KG1...
15.
Marchwicka A, Cebrat M, Sampath P, Sniezewski L, Marcinkowska E
Front Oncol
. 2014 Jun;
4:125.
PMID: 24904835
The concept of differentiation therapy of cancer is ~40 years old. Despite many encouraging results obtained in laboratories, both in vitro and in vivo studies, the only really successful clinical...
16.
Gocek E, Marchwicka A, Bujko K, Marcinkowska E
PLoS One
. 2014 Mar;
9(3):e91752.
PMID: 24642534
Acute myeloid leukemia (AML) cell lines can be driven to differentiate to monocyte-like cells by 1,25- dihydroxyvitamin D3 (1,25D) and to granulocyte-like cells by all-trans-retinoic acid (ATRA). Both compounds activate...
17.
Gocek E, Baurska H, Marchwicka A, Marcinkowska E
Leuk Res Treatment
. 2012 Dec;
2012:713243.
PMID: 23213549
1α,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D) exerts its biological activities through vitamin D receptor (VDR), which is a member of the superfamily of steroid receptors, that act as ligand-dependent transcription factors. Ligated VDR...
18.
Gocek E, Marchwicka A, Baurska H, Chrobak A, Marcinkowska E
J Steroid Biochem Mol Biol
. 2012 Jul;
132(3-5):220-6.
PMID: 22789609
Some leukemic cell lines can be driven to differentiate to monocyte-like cells by 1,25-dihydroxyvitamin D(3) (1,25D) and to granulocyte-like cells by all-trans retinoic acid (ATRA). Acute myloid leukemias (AMLs) are...
19.
Baurska H, Marchwicka A, Klopot A, Kutner A, Marcinkowska E
Oncol Rep
. 2012 Jul;
28(3):1110-6.
PMID: 22751936
1,25-Dihydroxyvitamin D3 (1,25D) is implicated in many cellular functions including cell proliferation and differentiation, thus, exerting potential antitumor effects. A major limitation for therapeutic use of 1,25D are its potent...